REGENXBIO Employee Directory
Biotechnology ResearchMaryland, United States201-500 Employees
REGENXBIO is a clinical-stage biotechnology company based in Rockville, Maryland, at 9804 Medical Center Drive, Rockville, MD 20850, United States. Founded in 2009, the company has developed the AAV Therapeutics platform, a gene therapy modality intended to be one-time treatments. It is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for wet AMD and diabetic retinopathy through a collaboration with AbbVie, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for spinal muscular atrophy. The company operates in the biotechnology research industry and employs between 201 and 500 people.